⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
CAR T Cell Senolytic Therapy
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-11-09 — Senescence-targeted engineered CAR-T immunotherapy: advances, challenges and perspectives for engineered senolytic immunotherapy.: [expert-opinion] Review, no new primary data: the authors propose an evaluation framework and translational roadmap for senescence-targeted CAR-T therapy, emphasizing unresolved antigen specificity and aged-microenvironment immunosuppression rather than demonstrated precision or healthspan benefit in humans. [expert-opinion] (novelty: 3)
- 2026-09-29 — uPAR‐Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non‐Human Primates With Serum Aminotransferase Activity as a Safety Monitor: cross-connection with upar-bispecific-tce-senolytic: Both are immuno-senolytic cell-engaging modalities targeting senescent-cell surface antigens; the uPAR-targeting bispecific T-cell engager is an off-the-shelf, titratable (dose-adjustable via aminotransferase monitoring) alternative to engineered CAR-T senolytics, with the same mechanistic reliance on recruiting endogenous T cells to kill senescent targets. (novelty: 4)
- 2026-09-03 — Aging microenvironment induces CD8T cell exhaustion by suppressing hepatic β-hydroxybutyrylate synthesis.: cross-connection with beta-hydroxybutyrate-3hb: The aged hepatic BDH1–3HB axis gates CD8 T-cell exhaustion; 3HB supplementation rescued CAR-T efficacy in aged hosts, linking ketone metabolism to engineered T-cell therapy performance in older recipients. (novelty: 4)
- 2026-10-01 — uPAR-Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non-Human Primates With Serum Aminotransferase Activity as a Safety Monitor.: cross-connection with upar-bispecific-tce-senolytic: Both redirect T cells against uPAR+ senescent cells; the bispecific engager trades CAR-T’s durable engineered persistence for pharmacologic dose-titratability guided by aminotransferase monitoring. (novelty: 4)
- 2026-09-23 — Targeting BIRC6 rejuvenates hematopoietic stem cell aging and immunosenescence.: cross-connection with birc6-inhibition: Both are targeted-delivery approaches to rejuvenate the hematopoietic/immune compartment; BIRC6 LNP-ASOs use antibody-directed nanoparticles to HSCs, while CAR-T senolytics use engineered T cells against senescent-cell surface markers. (novelty: 4)
- 2026-06-12 — Chimeric Antigen Receptor T Cells as Living Therapeutics Targeting Senescence and Age-Related Diseases.: Systematic review synthesizes the emerging CAR T senolytic paradigm — senescent-cell surface target discovery, engineering for the aged/senescent niche, and preclinical reversal of fibrosis and metabolic dysfunction — without new primary human efficacy data; open issues remain around target specificity, on-target/off-tumor toxicity, and manufacturing. [animal-model] (novelty: 3)
Open questions
Related
Contributing findings
Senescence-targeted engineered CAR-T immunotherapy: advances, challenges and perspectives for engineered senolytic immunotherapy.
09-nov-2026
novelty 3
per-area 3
strengthens
Chimeric Antigen Receptor T Cells as Living Therapeutics Targeting Senescence and Age-Related Diseases.
12-jun-2026
novelty 3
per-area 3
strengthens